Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model-Reference-Cited by-同舟云学术

Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model

Published:2020-02-20 Issue:3 Volume:88 Page:
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Mangas Kirstie M.¹,Buultjens Andrew H.¹,Porter Jessica L.¹,Baines Sarah L.¹,Marion Estelle²,Marsollier Laurent²,Tobias Nicholas J.³⁴,Pidot Sacha J.¹,Quinn Kylie M.⁵,Price David J.⁶⁷,Kedzierska Katherine¹,Zeng Weiguang¹,Jackson David C.¹,Chua Brendon Y.¹,Stinear Timothy P.¹^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia

2. CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France

3. Molekulare Biotechnologie, Fachbereich Biowissenschaften, Goethe-Universität Frankfurt, Frankfurt am Main, Germany

4. LOEWE Centre for Translational Biodiversity in Genomics (TBG), Frankfurt am Main, Germany

5. Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia

6. Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection & Immunity, The University of Melbourne and Royal Melbourne Hospital, Parkville, Victoria, Australia

7. Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Victoria, Australia

Abstract

The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with Mycobacterium ulcerans . There is no effective vaccine. Here, we assessed an experimental prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl reductase (ER) domain of the M. ulcerans mycolactone polyketide synthases electrostatically coupled with a previously described Toll-like receptor 2 (TLR-2) agonist-based lipopeptide adjuvant, R 4 Pam 2 Cys.

Funder

Department of Health | National Health and Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.00753-19

Reference109 articles.

1. Histopathologic Features ofMycobacterium ulceransInfection

2. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study

3. The pathology of mycobacterium ulcerans infection